An algorithm for individual dosage in cadmium–zinc–telluride spect-gated radionuclide angiography
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
An algorithm for individual dosage in cadmium–zinc–telluride spect-gated radionuclide angiography. / Hansen, Maria Normand; Haarmark, Christian; Kristensen, Bent; Zerahn, Bo.
In: Diagnostics, Vol. 11, No. 12, 2268, 2021.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - An algorithm for individual dosage in cadmium–zinc–telluride spect-gated radionuclide angiography
AU - Hansen, Maria Normand
AU - Haarmark, Christian
AU - Kristensen, Bent
AU - Zerahn, Bo
N1 - Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021
Y1 - 2021
N2 - The aim of the present study was to test an individualised dose without compromising the ease of analysing data when performing equilibrium radionuclide angiography (ERNA) using cadmium–zinc–telluride (CZT) SPECT. From March 2018 to January 2019, 1650 patients referred for ERNA received either an individualised dose of99m Tc-labeled human serum albumin (HSA) according to their age, sex, height, and weight (n = 1567), or a standard dose of 550 MBq (n = 83). The target count rate (CRT ) was reduced every two months from 2.7 to 1.0 kcps. A final test with a CRT of 1.7 kcps was run for three months to test whether an agreement within 2% points for the determination of LVEF, on the basis of only two analyses, was obtainable in at least 95% of acquisitions. All the included ERNAs were performed on a dedicated cardiac CZT SPECT camera. When using the algorithm for an individualised dose, we found that agreement between the measured and predicted count rate was 80%. With a CRT of 1.7 kcps, the need for more than two analyses to obtain sufficient agreement for LVEF was 4.9%. Furthermore, this resulted in a mean dose reduction from 550 to 258 MBq. Patients’ weight, height, sex, and age can, therefore, be used for individualising a tracer dose while reducing the mean dose.
AB - The aim of the present study was to test an individualised dose without compromising the ease of analysing data when performing equilibrium radionuclide angiography (ERNA) using cadmium–zinc–telluride (CZT) SPECT. From March 2018 to January 2019, 1650 patients referred for ERNA received either an individualised dose of99m Tc-labeled human serum albumin (HSA) according to their age, sex, height, and weight (n = 1567), or a standard dose of 550 MBq (n = 83). The target count rate (CRT ) was reduced every two months from 2.7 to 1.0 kcps. A final test with a CRT of 1.7 kcps was run for three months to test whether an agreement within 2% points for the determination of LVEF, on the basis of only two analyses, was obtainable in at least 95% of acquisitions. All the included ERNAs were performed on a dedicated cardiac CZT SPECT camera. When using the algorithm for an individualised dose, we found that agreement between the measured and predicted count rate was 80%. With a CRT of 1.7 kcps, the need for more than two analyses to obtain sufficient agreement for LVEF was 4.9%. Furthermore, this resulted in a mean dose reduction from 550 to 258 MBq. Patients’ weight, height, sex, and age can, therefore, be used for individualising a tracer dose while reducing the mean dose.
KW - CZT SPECT
KW - Gated SPECT
KW - Personalised medicine
KW - RNA
U2 - 10.3390/diagnostics11122268
DO - 10.3390/diagnostics11122268
M3 - Journal article
C2 - 34943505
AN - SCOPUS:85121544775
VL - 11
JO - Diagnostics
JF - Diagnostics
SN - 2075-4418
IS - 12
M1 - 2268
ER -
ID: 290253293